| Autor: |
Stephanie G, Craig, Lesley A, Anderson, Andrew G, Schache, Michael, Moran, Laura, Graham, Keith, Currie, Keith, Rooney, Max, Robinson, Navdeep S, Upile, Rachel, Brooker, Mina, Mesri, Victoria, Bingham, Stephen, McQuaid, Terry, Jones, Dennis J, McCance, Manuel, Salto-Tellez, Simon S, McDade, Jacqueline A, James |
| Rok vydání: |
2018 |
| Předmět: |
|
| Zdroj: |
British Journal of Cancer |
| ISSN: |
1532-1827 |
| Popis: |
Background TNM8 staging for oropharyngeal squamous cell carcinomas (OPSCC) surrogates p16 immunohistochemistry for HPV testing. Patients with p16+ OPSCC may lack HPV aetiology. Here, we evaluate the suitability of TNM8 staging for guiding prognosis in such patients. Methods HPV status was ascertained using p16 immunohistochemistry and high-risk HPV RNA and DNA in situ hybridisation. Survival by stage in a cohort of OPSCC patients was evaluated using TNM7/TNM8 staging. Survival of p16+/HPV− patients was compared to p16 status. Results TNM8 staging was found to improve on TNM7 (log rank p = 0·0190 for TNM8 compared with p = 0·0530 for TNM7) in p16+ patients. Patients who tested p16+ but were HPV− (n = 20) had significantly reduced five-year survival (33%) compared to p16+ patients (77%) but not p16− patients (35%). Cancer stage was reduced in 95% of p16+/HPV− patients despite having a mortality rate twice (HR 2.66 [95% CI: 1.37–5.15]) that of p16+/HPV+ patients under new TNM8 staging criteria. Conclusion Given the significantly poorer survival of p16+/HPV− OPSCCs, these data provide compelling evidence for use of an HPV-specific test for staging classification. This has particular relevance in light of potential treatment de-escalation that could expose these patients to inappropriately reduced treatment intensity as treatment algorithms evolve. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink